Medical Therapy. Efficacy or Lack of Efficacy

Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension

Satoshi Akagi, Shingo Kasahara, Teiji Akagi, Kentaro Ejiri, Toshiharu Mitsuhashi, Koji Nakagawa, Kazufumi Nakamura, Hiroshi ItoOkayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences. Johns Hopkins Bloomberg School of Public Health. Okayama University Hospital.Japan and United States Journal of the American College of Cardiology AdvancesJACC Adv 2024; 3:DOI: 10.1016/j.jacadv.2024.100887 AbstractBackground: A treatment strategy for congenital heart defects […]

Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension Read More »

Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia

Nidhy P. Varghese, Gabriel Altit, Megan M. Gubichuk, Roopa SiddaiahBaylor College of Medicine and Texas Children’s Hospital. Montreal Children’s Hospital and McGill University. Children’s Mercy Hospital. Penn State Health Children’s Hospital.United States and Canada Journal of Clinical MedicineJ Clin Med 2024; 13: DOI: 10.3390/jcm13123417 AbstractAdvances in perinatal intensive care have significantly enhanced the survival rates of

Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia Read More »

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants

Amit V. Krishnan, Victoria Freniere, Rakesh Sahni, Diana P. Vargas Chaves, Sankaran S. Krishnan, Dimitrios Savva, Usha S. KrishnanColumbia University Irving Medical Center and New York-Presbyterian Hospital. New York Medical College.United States ChildrenChildren 2024; DOI: 10.3390/children11060703 AbstractThis is a single-center retrospective study to assess the safety and tolerability of continuous inhaled iloprost use as rescue therapy

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants Read More »

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition

Xinyu Lia, Hui Li, Bo Feng, Xiaoyan Chen, Ting Chen, Jiafei Lu, Huating Xie, Nana Su, Houlin Chen, Chenghao Lou, Runxin Zhuang, Xi Chen, Shengwei Jin, Yu HaoSecond Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University. Ruijin Hospital and Shanghai Jiao Tong University School of Medicine. China Biomedicine and PharmacotherapyBiomed Pharmacother 2024; DOI: 10.1016/j.biopha.2024.117023

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition Read More »

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension

Brian S. Hernandez, Rod M. Shinozaki, R. Mark Grady, Andrea Drussa, Erica Jamro-Comer, Jinli Wang, Manish AggarwalWashington University School of Medicine. Loma Linda University Children’s Hospital. United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114116 AbstractObjective: To assess the effect of treating pulmonary hypertension (PH) in infants less than 1 year of age with systemic glucocorticoids while

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension Read More »

Chylothorax in Infants and Children After Congenital Heart Surgery: Approach and Review

Anil Kumar, Sristy Agarwal, Reena Khantwal, Arun Gupta, Siddhartha C. Rudrappa, Neeraj Aggarwal, Raja JoshiSir Ganga Ram Hospital. India World Journal of Pediatric and Congenital Heart SurgeryWorld J Pediatr Congenit Heart Surg 2024; DOI: 10.1177/21501351241237952 AbstractChylothorax in infants after surgery for congenital heart disease is associated with significant morbidity and mortality. Numerous management modalities applied alone

Chylothorax in Infants and Children After Congenital Heart Surgery: Approach and Review Read More »

Incidence, Risk Factors and Effective Treatment Strategies for Chylothorax After Pediatric Heart Surgeries: Retrospective Analysis of Large Database in Single Institution

Muhammad Shahzada, Yasser A. Alheraish, Reem M. E. Beheri, Bushra Algethami, Patricia Machado, Gamal Mohamed, Fared Khouqeer, Zohair Al HaleesKing Faisal Specialist Hospital and Research Center.Saudi Arabia Journal of the Saudi Heart AssociationJ Saudi Heart Assoc 2023; 35: 169-176DOI: 10.37616/2212-5043.1341 AbstractBackground: Risk factors for postoperative chylothorax in children who had cardiothoracic procedures are not always clear. Due

Incidence, Risk Factors and Effective Treatment Strategies for Chylothorax After Pediatric Heart Surgeries: Retrospective Analysis of Large Database in Single Institution Read More »

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Mandana Kashaki, Arash Mohazzab, Mohammad Radgoudarzi, Arash Bordbar, Sama DabbaghIran University of Medical Sciences. Shahid Akbar Abadi Hospital. Iran Pediatrics and NeonatologyPediatr Neonatol 2024; DOI: 10.1016/j.pedneo.2023.12.007 AbstractBackground: Persistent Pulmonary Hypertension of the newborn (PPHN) is characterized by sustained elevated Pulmonary Artery Pressure (PAP). Drug resistance and the adverse effects of current therapeutic agents warrant investigation of other

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial Read More »

Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation

Michele Lioncino, Adelaide Fusco, Emanuele Monda, Diego Colonna, Martina Caiazza, Michelina Sibilio, Daniela Magri, Angela Carla Borrelli, Barbara D’Onofrio, Maria Luisa Mazzella, Rossella Colantuono, Maria Rosaria Arienzo, Berardo Sarubbi, Maria Giovanna Russo, Giovanni Chello, Giuseppe LimongelliUniversity of Campania “Luigi Vanvitelli” and Monaldi Hospital. University College of London and St. Bartholomew’s Hospital.Italy and United Kingdom GenesGenes

Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation Read More »

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients

Khaled Ahmed Shams, Dalia Monir Ellahony, Ahmed Fouad Halima, Rania Salah ElzayatHelwan University. Magdi Yacoub Foundation. Menoufia University.Egypt Egypt Heart JournalEgypt Heart J 2024; 76:DOI: 10.1186/s43044-024-00475-5 AbstractBackground: Children with ventricular septal defect (VSD) and large systemic-to-pulmonary shunts eventually develop pulmonary hypertension (PH). The perioperative management of patients with VSD and PH is quite troublesome and still debatable,

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients Read More »

Scroll to Top